NEWS & VIEWS

Global private equity and venture capital news and research

Posts Tagged ‘biopharmaceuticals’

9 July 2014

Remiges Biopharma nears halfway mark for debut fundp

bio Biopharmaceutical venture capital firm Remiges Biopharma, which was recently launched by former Mitsui executives, is nearing the halfway mark in its debut fundraise, AltAssets can reveal.

4 June 2014

Deerfield backs KemPharm with $60m investment

biotech_lrg Healthcare-focused investment firm Deerfield Management Company has backed clinical stage biopharmaceutical company KemPharm with a $60m investment.

27 May 2014

UPDATE: FreshTracks nears final close for third fundp

FreshTracks Venture capital firm FreshTracks Capital is set to close its third fund on June 30, according to a person with direct knowledge of the matter.

21 May 2014

Venture capital-backed Kite Pharma files for IPO

cancer band pink_sq Venture capital-backed biopharmaceutical startup Kite Pharma has filed for an IPO.

23 April 2014

OrbiMed leads $22m round for Aerpio Therapeutics

biotech_lrg Biopharmaceutical startup Aerpio Therapeutics has secured $22m in a round led by venture capital firm OrbiMed.

17 April 2014

Venture capital-backed Epirus raises $36m, merges with Nasdaq-listed Zalicus

biotech_lrg Boston-based startup Epirus Biopharmaceuticals has secured $36m in a Series B round led by Livzon Mabpharm and agreed to merge with Nasdaq-listed group Zalicus.

13 March 2014

OrbiMed helps Sage Therapeutics raise $38m

medical monitor Healthcare-focused investment firm OrbiMed Advisors participated in a $38m Series C round for biopharmaceutical company Sage Therapeutics.

7 February 2014

Venture capital-backed Auspex prices IPO at $12 per share

shares stocks IPO Venture capital-backed biopharmaceutical company Auspex Pharmaceuticals has priced its IPO on the Nasdaq exchange at $12 per share.

11 December 2013

Life science venture capital firm Pappas Ventures hires Roche chairman Franz Humer

Life science venture capital firm Pappas Ventures has appointed Franz Humer, chairman of pharmaceutical giant Roche, as a venture partner and senior advisor with the firm.

4 December 2013

Biotech company Zafgen raises $45m Series E

biotech_lrg Biopharmaceutical business Zafgen has raised $45m in a Series E round to fund the development of its obesity therapeutic beloranib.

Page 1 of 212

Legals & Terms of UsePrivacy Policy


AltAssets is registered as a trademark of Investor Networks Limited (06695690).
Registered Office: Zetland House, 5-25 Scrutton St, London EC2A 4HJ
Content is © AltAssets 2000-2014